Loading...
Loading...
India's metformin imports from TURKEY total $2110.6B across 255 shipments from 9 foreign suppliers. NOVARTIS PHARMA AG leads with $2110.6B in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include NOVARTIS HEALTHCARE PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for metformin โ a diversified sourcing base with multiple active suppliers from TURKEY.

NOVARTIS PHARMA AG is the leading Metformin supplier from TURKEY to India, with import value of $2110.6B across 232 shipments. The top 5 suppliers โ NOVARTIS PHARMA AG, M/S. NOVARTIS PHARMA AG, BILIM ILAC SAN VE TIC A.S., ABDI IBRAHIM ILAC SAN VE TIC A S, SANOVAL ILAC SAN. VE TIC. A.S โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | NOVARTIS PHARMA AG | $2110.6B | 232 | 100.0% |
| 2 | M/S. NOVARTIS PHARMA AG | $7.0K | 3 | 0.0% |
| 3 | BILIM ILAC SAN VE TIC A.S. | $2.1K | 2 | 0.0% |
| 4 | ABDI IBRAHIM ILAC SAN VE TIC A S | $458 | 3 | 0.0% |
| 5 | SANOVAL ILAC SAN. VE TIC. A.S | $59 | 1 | 0.0% |
| 6 | ABDI IBRAHIM ILAC SAM VE TI|C A.S | $50 | 7 | 0.0% |
| 7 | ABDI IBRAHIM ILAC SAN VE TIC A.S. | $48 | 2 | 0.0% |
| 8 | SANTA FARMA ILAC SANAYI.A.S | $6 | 3 | 0.0% |
| 9 | SANTA FARMA ILAC SANAYI A S | $0 | 2 | 0.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | NOVARTIS HEALTHCARE PRIVATE LIMITED | $2110.6B | 235 | 100.0% |
| 2 | ACCUTEST RESEARCH LABORATORIES INDIA PRIVATE LIMIT | $2.1K | 2 | 0.0% |
| 3 | VEEDA CLINICAL RESEARCH PVT LTD |
TURKEY โ India trade corridor intelligence
The Turkey to India trade corridor has experienced stable conditions between 2025 and 2026. Ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra have maintained efficient operations with minimal congestion. Freight rates have remained consistent, and the exchange rate between the Indian Rupee (INR) and the Turkish Lira has been favorable for trade.
The Production Linked Incentive (PLI) scheme and import substitution policies have been implemented to reduce dependency on imports and promote domestic manufacturing. These initiatives may impact the volume of finished formulation imports from Turkey, as India aims to enhance self-reliance in pharmaceutical production.
India and Turkey have established a robust trade relationship, with ongoing negotiations for a Free Trade Agreement (FTA) to further enhance bilateral trade. Mutual recognition of Good Manufacturing Practices (GMP) has been achieved, facilitating smoother pharmaceutical trade. Pharmaceutical trade facilitation measures have been implemented to streamline processes and reduce barriers.
| $458 |
| 3 |
| 0.0% |
| 4 | QPS BIOSERVE INDIA PRIVATE LIMITED | $59 | 1 | 0.0% |
| 5 | AZIDUS LABORATORIES LIMITED | $56 | 12 | 0.0% |
| 6 | VEEDA CLINICAL RESEARCH LIMITED | $48 | 2 | 0.0% |
The landed cost of importing finished Metformin formulations from Turkey to India includes the Free On Board (FOB) price from Turkey, freight charges, insurance, Basic Customs Duty of 10%, Education Cess of 2%, Secondary Higher Education Cess of 1%, Countervailing Duty (CVD) of 6%, Goods and Services Tax (GST), port handling fees, and Customs House Agent (CHA) charges. Per-unit estimates depend on the specific product and shipping terms.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Metformin into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, approval under Rule 122E is necessary before registration or import. Applications for registration and import should be submitted to the Licensing Authority under the Act, i.e., the Drugs Controller General (I) at CDSCO.
Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, with Certificates of Analysis (CoA) provided for each batch. Stability data must comply with International Council for Harmonisation (ICH) guidelines for Zone IV. The formulations must meet the standards set by the Indian Pharmacopoeia. Port inspections by customs drug inspectors are conducted to ensure compliance.
Between 2024 and 2026, the CDSCO has implemented regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Turkey have been established to facilitate pharmaceutical trade, including mutual recognition of Good Manufacturing Practices (GMP).
Market demand, customs duty structure, and competitive landscape ยท Import duty: 17.10%
India imports finished Metformin formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity may not fulfill the entire market demand, leading to reliance on imports. The market size for Metformin formulations in India is substantial, driven by the prevalence of diabetes and the need for diverse formulations.
The import duty structure for pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty of 10%, Education Cess of 2%, Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%, totaling 17.10%. Additional taxes such as the Goods and Services Tax (GST) may apply. Exemptions and preferential rates may be available under specific conditions or agreements.
India sources finished Metformin formulations from Turkey due to competitive advantages such as patented formulations, specialized dosage forms, and high-quality manufacturing standards. Other suppliers include China, Germany, and the United States. Turkey's share in the Indian market is significant, offering unique formulations not readily available from other sources.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Metformin formulations from Turkey due to strategic reasons such as access to patented formulations, specialized dosage forms, and technology-licensed products. Turkey supplies specific formulations that India does not manufacture domestically, fulfilling market needs and patient requirements.
Compared to other origins like China, the European Union, and the United States, Turkey offers competitive pricing, high-quality products, and reliable regulatory compliance. Turkey's unique advantage lies in its ability to provide specialized formulations and maintain consistent quality standards.
Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to geopolitical tensions and logistical challenges. Mitigation strategies include diversifying suppliers and maintaining buffer stocks.
Import license checklist, document requirements, quality testing, and compliance
Upon arrival, customs drug inspectors conduct port inspections, including mandatory batch testing and sample collection. Timelines for testing vary, and if a batch fails, it may be rejected or require reprocessing. Common quality issues from Turkey include labeling discrepancies and stability concerns.
Annual renewal of CDSCO registration is mandatory. Periodic audits in Turkey ensure continued compliance with Indian regulations. Change control procedures must be documented, and pharmacovigilance systems should be in place. Post-import monitoring is required, and import records must be maintained as per the Drugs and Cosmetics Act.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Metformin suppliers from TURKEY to India include NOVARTIS PHARMA AG, M/S. NOVARTIS PHARMA AG, BILIM ILAC SAN VE TIC A.S.. The leading supplier is NOVARTIS PHARMA AG with import value of $2110.6B USD across 232 shipments. India imported Metformin worth $2110.6B USD from TURKEY in total across 255 shipments.
India imported Metformin worth $2110.6B USD from TURKEY across 255 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Metformin sourced from TURKEY include NOVARTIS HEALTHCARE PRIVATE LIMITED, ACCUTEST RESEARCH LABORATORIES INDIA PRIVATE LIMIT, VEEDA CLINICAL RESEARCH PVT LTD. The largest buyer is NOVARTIS HEALTHCARE PRIVATE LIMITED with $2110.6B in imports across 235 shipments.
The total value of Metformin imports from TURKEY to India is $2110.6B USD, across 255 shipments and 9 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
255 Verified Shipments
9 suppliers, 6 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists